Octreotide therapy in dumping syndrome: Analysis of long-term results

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 9, 2006, Pages 1367-1375

  Didden, P ^a   Penning, C ^a   Masclee, A A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FECES LIPID; OCTREOTIDE;

ADULT; AGED; ARTICLE; DEATH; DEFECATION DISORDER; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GALLSTONE FORMATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; POSTGASTRECTOMY SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; STEATORRHEA; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DUMPING SYNDROME; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OCTREOTIDE; TREATMENT OUTCOME;

EID: 33750034108     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03124.x     Document Type: Article

References (32)

1. Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am 1992; 72: 445-65.
2. Vecht J, Masclee AAM, Lamers CBHW. The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment. Scand J Gastroenterol 1997; 223: 21-7.
3. Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue Sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal man. Digestion 1987; 36: 108-24.
4. Hasler WL, Soudah HC, Owyang C. Mechanisms by which octreotide ameliorates symptoms in the dumping syndrome. J Pharmacol Exp Ther 1996; 277: 1359-65.
5. Geer RJ, Richards WO, O'Dorisio TM, et al. Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome. Ann Surg 1990; 212: 678-87.
6. Richards WO, Geer R, O'Dorisio TM, et al. Octreotide acetate induces fasting small bowel motility in patients with dumping syndrome. J Surg Res 1990; 49: 483-7.
7. Kooner JS, Peart WS, Mathias CJ. The peptide release inhibitor, octreotide (SMS 210-995), prevents the haemodynamic changes following food ingestion in normal human subjects. Q J Exp Physiol 1989; 74: 569-72.
8. Primrose JN. Octreotide in the treatment of the dumping syndrome. Digestion 1990; 45: 49-58.
9. Mackie CR, Jenkins SA, Hartley MN. Treatment of severe postvagotomy/postgastrectomy symptoms with the somatostatin analogue octreotide. Br J Surg 1991; 78: 1338-43.
10. Vecht J, Lamers CBHW, Masclee AAM. Long-term results of octreotide-therapy in severe dumping syndrome. Clin Endocrinol 1999; 51: 619-24.
11. Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg 1991; 126: 1231-5.
12. Tulassay Z, Tulassay T, Gupta R, et al. Long acting somatostatin analogue in dumping syndrome. Br J Surg 1989; 76: 1294-5.
13. Hopman WP, Wolberink RG, Lamers CB, et al. Treatment of dumping syndrome with the somatostain analogue SMS 201-95. Ann Surg 1988; 207: 155-9.
14. Penning C, Vecht J, Masclee AAM. Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome. Aliment Pharmacol Ther 2005; 22: 963-9.
15. van der Kley FGH, Vecht J, Lamers CBHW, Masclee AAM. Diagnostic value of dumping provocation in patients after gastric surgery. Scand J Gastroenterol 1996; 31: 1162-6.
16. van de Kamer JH, Huinink HTB, Weyers HA. Rapid method for determination of fat in feces. J Biol Chem 1949; 177: 349-55.
17. Eypasch E, Williams JI, Wood-Daupinee S, et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995; 82: 216-22.
18. Bevans JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Endocrinol Metab 2002; 87: 4554-63.
19. Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 2000; 53: 577-86.
20. Ricci S, Antonuzzo A, Galli L, Orlandini C, et al. Long-acting depot landreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23: 412-5.
21. Garland J, Buscome JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003; 17: 437-44.
22. Novartis. Sandostatin LAR: octreotide IM injection (online). Available at: http://www.sandostatin.com, accessed on 15 March 2006.
23. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993; 25: 375-9.
24. Bigg-Wither GW, Ho KK, Grunstein RR, Sullivan CE, Doust BD. Effects of long term octreotide on gall stone formation and gall bladder function. Br Med J 1992; 304: 1611-2.
25. Dowling RH, Hussaini SH, Murphy GM, Besser GM, Wass JA. Gallstones during octreotide therapy. Metabolism 1993; 54: 107-20.
26. Hussaini SH, Murphy GM, Kennedy C, Besser GM, Wass JAH, Dowling RH. The role of bile composition and physical chemistry in the pathogenesis of octreotide associated gallbladder stones. Gastroenterology 1994; 107: 1503-13.
27. Hussaini SH, Pereira SP, Veysey MJ, et al. Roles of gallbladder emptying and intestinal transit in the pathogenesis of octreotide induced gallbladder stones. Gut 1996; 38: 775-83.
28. Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatine LAR. Aliment Pharmacol Ther 2001; 15: 181-5.
29. Hofmann AF. Increased deoxycholic acid absorption and gall stones in acromegalic patients treated with octreotide: more evidence for a connection between slow transit constipation and gall stones. Gut 2005; 54: 575-8.
30. Inoue K, Fuchigami A, Higashide S, et al. Gallbladder sludge and stone formation in relation to contractile function after gastrectomy. A prospective study. Ann Surg 1991; 215: 19-26.
31. Leth RD, Abrahammsson H, Kilander A, Lundell LR. Malabsorption of fat after partial gastric resection. A study of pathophysiologic mechanisms. Eur J Surg 1991; 157: 205-8.
32. Witt K, Pedersen NT. The long-acting somatostatin analogue SMS 201-995 causes malabsorption. Scand J Gastroenterol 1989; 24: 1248-52.